Demonstrating efficiency of drugs to raise white blood cell count - Wesley Research Institute
Wesley Research Institute

The aim of this study is to demonstrate the efficacy of Mavorixafor in patients with WHIM syndrome.


Research Objectives





Patient Group

Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM Syndrome)

Study location

Wesley Research Institute



Study type

Industry Sponsored
Sponsors: X4 Pharmaceuticals Incorporated

Lead investigators

  • Dr Daman Langguth

Clinical Trial Coordinator

  • Venita Bali

Technical title

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients with WHIM Syndrome with Open-Label Extension (4WHIM)

About this research project

WHIM syndrome is a rare genetic disease of the immune system that affects the body’s immune system ability to fight off infections. Patients diagnosed with WHIM syndrome have a deficiency in specific infection-fighting antibodies in the blood and have an extremely low level of infection fighting white blood cells called neutrophils, which move from the bone marrow into the bloodstream where they can patrol and protect the body.

Mavorixafor is a drug that is intended to release certain types of white blood cells (neutrophils and lymphocytes) from the bone marrow and to raise the number of white blood cells in blood circulation.

The more of these type of white blood cells you have in your blood the better your body can fight infection and as such, may help to reduce the number and severity of your infections.

The aim of this study is to demonstrate the efficacy of Mavorixafor in patients with WHIM syndrome.


Latest News

Mitsubishi Development announces largest Australian partnership

On Thursday 6 July Wesley Research Institute and Mitsubishi Development signed a new partnership, the largest for Mitsubishi Development in Australia, which will provide significant funding for Navicare over the next two years.
Maureen Stevenson accepting her 2023 Queensland Community Philanthropist of the Year Award

Maureen Stevenson Award

Maureen Stevenson received the 2023 Community Philanthropist of the Year Award at the Queensland Philanthropy Awards (QCF) held at Brisbane Town Hall.
Andrew Barron, Mandy Maysey and Dr Phil Mosley

Australian scientists prove medicinal cannabis can be a lifechanging treatment for people with Tourette Syndrome

Imagine the pain and embarrassment of violent movements and uncontrollable outbursts at school or work…that’s what life was like for Chris Wright (35) before he started a ground-breaking clinical trial of medicinal cannabis.
1 2 3 6
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram